Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: A prospective randomized study

International Journal of Urology

Volumn 18, Issue 7, 2011, Pages 515-520

  Maselli, Guevar ^a   Bergamasco, Luca ^a   Silvestri, Vanuska ^a   Gualà, Luana ^a   Pace, Gianna ^a   Vicentini, Carlo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Benign prostatic enlargement; Lower urinary tract symptoms; Phosphodiesterase type 5 inhibitors; Solifenacin; Tadalafil

Indexed keywords

SOLIFENACIN; TADALAFIL;

ADULT; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DRY EYE; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE SURGERY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STORAGE DISEASE; UROFLOWMETRY; XEROSTOMIA;

AGED; CARBOLINES; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 5 INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; THERAPEUTICS; URINATION DISORDERS; URODYNAMICS;

EID: 79959572233     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02772.x     Document Type: Article

References (31)

1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur. Urol. 2006; 49: 651-9.
2. Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA. Persistence or recurrence of symptoms after transurethral resection of the prostate: an urodynamic assessment. J. Urol. 1994; 152: 935-7.
3. Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomised controlled trials. J. Urol. 2001; 165: 1526-32.
4. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? Br. J. Urol. 1999; 83: 227-37.
5. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J. Urol. 2001; 166: 172-6.
6. American Urological Association (AUA) benign prostatic hyperplasia (BPH) Guideline Update Panel. Guideline on the Management of Benign Prostatic Hyperplasia. AUA 2006.
7. European Association of Urology Guidelines (EAU). Guidelines on Conservative Treatment of Nonneurogenic Male LUTS. EAU 2010.
8. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994; 151: 54-61.
9. Rosen R, Altwein J, Boyle P etal. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637-49.
10. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006; 97 (Suppl 2): 23-8.
11. Barry M, Fowler FJ, O'Leary M etal. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 1992; 148: 1549-57.
12. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
13. Taylor J, Harrison SCW, Assassa RP, McGrother CW, Leicestershire MRC Incontinence Study Group. The pattern and progression of lower urinary tract symptoms after transurethral prostatectomy compared with those seen in the general population. Eur. Urol. 2007; 51: 1023-30.
14. Mirone V, Imbimbo C, Sessa G etal. Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J. Urol. 2004; 172: 1386-9.
15. Deveaud CM, Macarak EJ, Kucich U, Ewalt DH, Abrams WR, Howard PS. Molecular analysis of collagens in bladder fibrosis. J. Urol. 1998; 160: 1518-27.
16. Dinis P, Silva J, Ribeiro MJ, Avelino A, Reis M, Cruz F. Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. Eur. Urol. 2004; 46: 88-94.
17. Araki I, Du S, Kamiyama M etal. Overexpression of epithelial sodium channels in epithelium of human urinary bladder with outlet obstruction. Urology 2004; 64: 1255-60.
18. Sui GP, Rothery S, Dupont E etal. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002; 90: 118-29.
19. Khan MA, Thompson CS, Dashwood MR etal. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr. Vasc. Pharmacol. 2003; 1: 27-31.
20. Andersson KE, Chapple CR, Hofner K. Future drugs for the treatment of benign prostatic hyperplasia. World J. Urol. 2002; 19: 436-42.
21. Chang S, Hypolite JA, Zderic A etal. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005; 289: 1124-30.
22. Schiff JD, Mulhall JP. The link between LUTS and ED: clinical and basic science evidence. J. Androl. 2004; 25: 470-8.
23. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J. Urol. 2008; 180: 1228-34.
24. Liquori G, Trombetta C, De Giorgi G etal. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J. Sex. Med. 2009; 6: 544-52.
25. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 2008; 53: 1236-44.
26. McVary KT, Monnig W, Camps JL etal. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 2007; 177: 1071-7.
27. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010; 105: 502-7.
28. Forgue ST, Patterson BE, Bedding AW etal. Tadalafil pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 2006; 61: 280.
29. Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur. Urol. 2008; 54: 543-62.
30. Gacci M, Del Populo G, Macchiarella A etal. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J. Urol. 2007; 178: 2040-3.
31. McVary K, Tubaro A, De Nunzio C. The motion: PDE5 inhibitotors are a promising therapy for benign prostatic hyperplasia. Eur. Urol. 2009; 56: 878-80.